Ann: FDA Grants Orphan Drug Designation for Revascor, page-218

This stock is a confidence trick and akin to receiving an email from a Nigerian prince asking for your bank account details.

it’s pretty amazing that so many people follow it and own shares, judging by the participation in this forum

after 20 years and having raised close to $A2bn it loses tens of millions per year and doesn’t have a path to profitability yet expenses have been ～A$100m per year for many years


the Dream-HF phase 3 trial for congestive heart failure was the
company’s hope and it failed primary and secondary endpoints. Reported reduction in heart attacks and stroke were from a very truncated subset of the trial’s 500+ patient population, only about 20%… basically an insignificant Phase 1/2 trial population… but just enough for the company to say it seems to raise more money to fund more trials.

there are many red flags such as:
-the same lead researcher/doctor for heart trials for over 15 years
-the same institutions always taking the raising (particularly M&G in London
-the same Australian broker for 20 years that exclusively does the raisings despite the company dangling the promise of raising fees to much larger brokers in order to get research coverage
-a wide range of potential diseases despite a lack of evidence to pursue trials, so as to increase potential market size for the company and raise the probability-adjusted valuation
-a history of trial failure and torched capital by other stem cell companies that have long gone out of business or been subsumed by MSB


in addition the price chart is awful, below the 2004 IPO price now and looks to be in very clear terminal decline.